Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Ispire Technology Q3 2026 Earnings Call - Cash Flow Inflection Point and Malaysia Manufacturing Advantage
Ispire Technology reported a revenue dip to $18.7 million for fiscal Q3 2026, but management framed the quarter as a decisive turning point in the company’s restructuring. Sequential cash grew by $468...
- Revenue declined to $18.7 million in fiscal Q3 2026, down from $26.2 million year-over-year, though the sequential drop was only 8%, marking the most resilient second-to-third quarter performance in company history.
- Sequential cash growth of $468,000 brought the cash balance to $18 million, reinforcing management’s confidence in reaching cash flow positivity in the second half of calendar 2026.
- Gross margin stood at 10.7%, with gross profit negatively impacted by $2.2 million in one-time product returns from a legacy cannabis customer no longer in the supply chain.
- +7 more takeaways
Collegium Pharmaceutical Q1 2026 Earnings Call - AZSTARYS Acquisition Accelerates ADHD Growth
Collegium Pharmaceutical reported a strong start to 2026, driven by a 36% year-over-year surge in Jornay PM net revenue to $38.9 million and a durable 4% growth in its pain portfolio. The company succ...
- Jornay PM net revenue surged 36% year-over-year to $38.9 million, driven by a 14% increase in prescriptions and a 17% expansion in the prescriber base to an all-time high of 30,000.
- The company announced a $650 million cash acquisition of AZSTARYS, a differentiated ADHD treatment, which is expected to close in the second quarter of 2026 after the Hart-Scott-Rodino waiting period expired.
- Total pain portfolio net revenues grew 4% year-over-year to $154.6 million, with BELBUCA up 2% and XTAMPZA ER up 7%, providing a stable cash flow foundation for the business.
- +9 more takeaways
Evolent Health Q1 2026 Earnings Call - Strong Q1 Execution Masks Exchange Headwinds, Performance Suite Dominates Growth
Evolent Health delivered a solid first quarter, with revenue of $496 million and adjusted EBITDA of $22 million, landing in line with expectations. The core narrative is one of disciplined execution a...
- Revenue of $496 million grew 9% sequentially (ex-ECP), while adjusted EBITDA came in at $22 million, meeting expectations.
- Medical Expense Ratio (MER) improved 150 basis points to 93%, supported by favorable prior year development that offset higher oncology prevalence.
- Performance Suite revenue surged 26% sequentially to $323 million, driven by the new Aetna launch and membership growth.
- +7 more takeaways
Primo Brands Q1 2026 Earnings Call - Direct Delivery Turnaround Drives Raised Growth Guidance
Primo Brands delivered a strong start to 2026, with first quarter comparable net sales rising 1.7% to $1.63 billion, driven by broad-based price mix and volume gains. The company raised its full year ...
- Comparable net sales grew 1.7% year-over-year to $1.63 billion, marking a return to top-line growth driven by price mix and volume.
- Full year comparable organic net sales guidance raised to 1%-3% from flat to 1%, reflecting stronger-than-expected first quarter performance.
- Direct delivery service levels improved significantly, with on-time-in-full rates exceeding 90% and customer net adds approaching breakeven in March.
- +7 more takeaways
Teleflex Q1 2026 Earnings Call - Divestitures on Track, New CEO Hired, and Margin Pressure from Recalls
Teleflex delivered a mixed first quarter, with revenue growth beating expectations but adjusted EPS falling as margin pressure mounted from tariffs and a third-party supplier recall. The company is ex...
- Teleflex Q1 2026 revenue grew 5.1% on a pro forma adjusted constant currency basis to $548.3 million, beating internal expectations and tracking within the 4.5%-5.5% full-year guidance range.
- Adjusted EPS fell 3.5% year-over-year to $1.39 due to margin pressure from tariffs, higher interest expense, and quality remediation charges linked to a third-party supplier recall.
- The company announced the appointment of Jason Weidman as the next President and CEO, effective June 8, 2026, bringing over 25 years of medical technology experience from Medtronic.
- +7 more takeaways
Alvotech Q1 2026 Earnings Call - Pipeline Resubmission and Manufacturing Diversification Drive 2027 Growth Outlook
Alvotech navigated a transitional quarter in Q1 2026, with revenues declining 20% year-over-year to $106 million as the company deliberately slowed production at its Reykjavik facility to address FDA ...
- Q1 2026 revenues declined 20% YoY to $106 million, driven by production slowdowns at the Reykjavik facility and timing of licensing milestones.
- Adjusted EBITDA came in at $24 million (23% margin), up from $21 million in Q1 2025, cushioned by licensing revenue and cost management.
- FDA is conducting a routine GMP surveillance inspection at the Reykjavik site, expected to close by end of day tomorrow; no new findings anticipated.
- +12 more takeaways
ESAB Corporation Q1 2026 Earnings Call - Record Sales and Strategic Acquisitions Drive Margin Expansion
ESAB Corporation reported record first quarter 2026 sales of $715 million, reflecting a 10% year-over-year increase driven by strong performance across its diversified global footprint. The company ge...
- Record Q1 2026 sales of $715 million, up 10% year-over-year, driven by strong execution and diversified global footprint.
- Adjusted EBITDA of $136 million, up 6% year-over-year, with adjusted EBITDA margin of 19%.
- Acquisitions EWM and Aktiv both grew double digits year-over-year, demonstrating strong integration and market momentum.
- +7 more takeaways
Zai Lab Q1 2026 Earnings Call - Zoci Data Strengthens Global BLA Path While Regional Revenue Faces Near-Term Pressure
Zai Lab reported a 6% year-over-year decline in Q1 2026 product revenue to $99.6 million, driven by generic competition for ZEJULA and price discounts on VYVGART, though the company expects sequential...
- Zoci demonstrated a 62.5% confirmed intracranial overall response rate in extensive-stage small cell lung cancer, with a best overall intracranial response rate approaching 69% and only 16% grade 3 or higher treatment-related adverse events, signaling a best-in-class safety and efficacy profile.
- The registrational Phase III DLLEVATE study for zoci is enrolling well and is on track to complete enrollment in the first half of 2027, positioning the company for an interim analysis and potential accelerated approval submission in 2028.
- Zai Lab announced global collaborations with Amgen and Boehringer Ingelheim to explore zoci in combination with T-cell engagers and PD-L1 inhibitors, leveraging complementary mechanisms to deepen and extend responses in small cell lung cancer.
- +12 more takeaways
Apyx Medical Q1 2026 Earnings Call - AYON Sales Surge Drives 32% Revenue Growth and Upward Guidance Revision
Apyx Medical delivered a robust first quarter, with total revenue jumping 32% year-over-year to $12.5 million, fueled by a 36% surge in surgical aesthetics sales. The AYON body contouring platform, la...
- Total revenue grew 32% year-over-year to $12.5 million, driven by a 36% increase in surgical aesthetics segment revenue to $10.7 million.
- AYON body contouring system sales are ramping rapidly, with approximately 80% of sales going to existing Renuvion customers and new accounts showing strong engagement.
- GLP-1 weight loss drug adoption is creating a structural tailwind, as patients seek surgical interventions for loose skin, with management citing early-stage adoption and significant long-term demand potential.
- +9 more takeaways
Victory Capital Q1 2026 Earnings Call - Record Flows and Aggressive Buybacks Fuel Growth
Victory Capital reported record-breaking first quarter results, driven by a massive $18.9 billion in long-term gross flows and a 77% year-over-year revenue jump to $388 million. The firm is clearly ca...
- Record Q1 2026 gross flows hit $18.9 billion, a 104% increase year-over-year, signaling strong distribution momentum.
- Total client assets reached $313 billion, with international AUM growing to $55 billion across 60 countries.
- VictoryShares ETF AUM surged 53% year-over-year to over $20 billion, with net flows of $1.3 billion for the quarter.
- +7 more takeaways